JCWO leads the Molecular Diagnostics Program (MDP) that provides a free of cost, early and specific diagnostic for the control and survival of patients that are affected by various types of cancer, mainly leukemia and solid tumors, as well as infectious diseases like HIV, in poor developing countries. This program is targeted to children and adults of all ages and genders, in poverty and extreme poverty. The MDP runs under strict regulations and guidelines, is certified by the international quality system 9001:2015 and approved by the bioethics committee of each partner hospital. This is the only program in the region diagnosing some genetic alterations, such as NMYC and MGMT, using molecular techniques.
Among the specialized tests conducted under the program are Acute Myeloid Leukemia (PML/RARa, FLT3/ITD, Inv. 16, RUNX1/RUNX1T1, BCR/ABL P190, BCR/ABL p210), Chronic Myeloid Leukemia (BCR/ABL p190, BCR/ABL p210), Acute Lymphoblastic Leukemia (TCF3/PBX1, KMT2A/AFF1, ETV6-RUNX1, BCR/ABL p190, BCR/ABL p210); solid tumors such as Glioblastomas (MGMT) and Neuroblastomas (N-MYC), and HIV viral envelope (ENV) and structural (GAG) proteins.
The MDP improves the quality of life of patients, their prognosis and response to treatment, and increases their survival rate due to the early detection, the stratification of the disease risk and the possibility of determining the best possible treatment option for the specific diagnosis. Additionally, the MDP benefits the families of patients by relieving them from the economic burden and psychological stress that comes with the disease.